Articles with public access mandates - MV MateosLearn more
Not available anywhere: 24
Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised …
M Dimopoulos, H Quach, MV Mateos, O Landgren, X Leleu, D Siegel, ...
The Lancet 396 (10245), 186-197, 2020
Mandates: US National Institutes of Health
Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 …
MA Dimopoulos, E Terpos, M Boccadoro, S Delimpasi, M Beksac, ...
The Lancet Oncology 22 (6), 801-812, 2021
Mandates: Government of Spain
Critical evaluation of ASO RQ-PCR for minimal residual disease evaluation in multiple myeloma. A comparative analysis with flow cytometry
N Puig, ME Sarasquete, A Balanzategui, J Martinez, B Paiva, H Garcia, ...
Leukemia 28 (2), 391-397, 2014
Mandates: Government of Spain
Lenalidomide plus dexamethasone versus observation in patients with high-risk smouldering multiple myeloma (QuiRedex): long-term follow-up of a randomised, controlled, phase 3 …
MV Mateos, MT Hernández, P Giraldo, J de la Rubia, F de Arriba, ...
The lancet oncology 17 (8), 1127-1136, 2016
Mandates: Government of Spain
International harmonization in performing and reporting minimal residual disease assessment in multiple myeloma trials
LJ Costa, BA Derman, S Bal, S Sidana, S Chhabra, R Silbermann, JC Ye, ...
Leukemia 35 (1), 18-30, 2021
Mandates: US National Institutes of Health
In vivo murine model of acquired resistance in myeloma reveals differential mechanisms for lenalidomide and pomalidomide in combination with dexamethasone
EM Ocio, D Fernández-Lázaro, L San-Segundo, L López-Corral, ...
Leukemia 29 (3), 705-714, 2015
Mandates: Government of Spain
Phenotypic identification of subclones in multiple myeloma with different chemoresistant, cytogenetic and clonogenic potential
T Paíno, B Paiva, JM Sayagués, I Mota, T Carvalheiro, LA Corchete, ...
Leukemia 29 (5), 1186-1194, 2015
Mandates: Government of Spain
Treatment for patients with newly diagnosed multiple myeloma in 2015
MV Mateos, EM Ocio, B Paiva, L Rosiñol, J Martínez-López, J Bladé, ...
Blood Reviews 29 (6), 387-403, 2015
Mandates: Government of Spain
Bortezomib and thalidomide maintenance after stem cell transplantation for multiple myeloma: a PETHEMA/GEM trial
L Rosiñol, A Oriol, AI Teruel, AL De La Guía, MJ Blanchard, ...
Leukemia 31 (9), 1922-1927, 2017
Mandates: Government of Spain
Circulating tumor cells for the staging of patients with newly diagnosed transplant-eligible multiple myeloma
JJ Garcés, MT Cedena, N Puig, L Burgos, JJ Perez, L Cordon, ...
Journal of Clinical Oncology 40 (27), 3151-3161, 2022
Mandates: Cancer Research UK, European Commission, Government of Spain, AIRC …
A phase II trial of lenalidomide, dexamethasone and cyclophosphamide for newly diagnosed patients with systemic immunoglobulin light chain amyloidosis
MT Cibeira, A Oriol, JJ Lahuerta, MV Mateos, J de la Rubia, ...
British journal of haematology 170 (6), 804-813, 2015
Mandates: Government of Spain
Outcomes with two different schedules of bortezomib, melphalan, and prednisone (VMP) for previously untreated multiple myeloma: matched pair analysis using long-term follow-up …
MV Mateos, A Oriol, J Martínez-López, AI Teruel, E Bengoechea, ...
Annals of hematology 95, 2033-2041, 2016
Mandates: Government of Spain
Clinical applicability and prognostic significance of molecular response assessed by fluorescent‐PCR of immunoglobulin genes in multiple myeloma. Results from a GEM/PETHEMA study
J Martinez‐Lopez, E Fernández‐Redondo, R García‐Sánz, ...
British journal of haematology 163 (5), 581-589, 2013
Mandates: Government of Spain
Circulating tumor cells for comprehensive and multiregional non-invasive genetic characterization of multiple myeloma
JJ Garcés, G Bretones, L Burgos, R Valdes-Mas, N Puig, MT Cedena, ...
Leukemia 34 (11), 3007-3018, 2020
Mandates: Cancer Research UK, European Commission, Government of Spain, AIRC …
Prediction of peripheral neuropathy in multiple myeloma patients receiving bortezomib and thalidomide: a genetic study based on a single nucleotide polymorphism array
R García‐Sanz, LA Corchete, M Alcoceba, MC Chillon, C Jiménez, ...
Hematological Oncology 35 (4), 746-751, 2017
Mandates: Government of Spain
A machine learning model based on tumor and immune biomarkers to predict undetectable MRD and survival outcomes in multiple myeloma
C Guerrero, N Puig, MT Cedena, I Goicoechea, C Perez, JJ Garcés, ...
Clinical Cancer Research 28 (12), 2598-2609, 2022
Mandates: Cancer Research UK, European Commission, Government of Spain, AIRC …
The predominant myeloma clone at diagnosis, CDR3 defined, is constantly detectable across all stages of disease evolution
N Puig, I Conde, C Jiménez, ME Sarasquete, A Balanzategui, M Alcoceba, ...
Leukemia 29 (6), 1435-1437, 2015
Mandates: Government of Spain
Circulating tumor and immune cells for minimally invasive risk stratification of smoldering multiple myeloma
R Termini, D Žihala, E Terpos, A Perez-Montaña, T Jelínek, M Raab, ...
Clinical Cancer Research 28 (21), 4771-4781, 2022
Mandates: Cancer Research UK, European Commission, Government of Spain, AIRC …
Evaluating gene expression profiling by quantitative polymerase chain reaction to develop a clinically feasible test for outcome prediction in multiple myeloma
ME Sarasquete, J Martínez‐López, MC Chillón, M Alcoceba, LA Corchete, ...
British journal of haematology 163 (2), 223-234, 2013
Mandates: Government of Spain
Definition and clinical significance of the monoclonal gammopathy of undetermined significance–like phenotype in patients with monoclonal gammopathies
L Burgos, LE Tamariz-Amador, N Puig, MT Cedena, C Guerrero, T Jelínek, ...
Journal of Clinical Oncology 41 (16), 3019-3031, 2023
Mandates: Cancer Research UK, European Commission, Government of Spain, AIRC …
Publication and funding information is determined automatically by a computer program